MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
Safety notice from a federal regulator
Headline as published by U.S. Food and Drug Administration (MedWatch) on Nov 9, 2026; collected by the wire Nov 9, 2026, 1:15 PM ET.
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
Coverage
Named in this story
- AgencyU.S. Food and Drug AdministrationMatched on
FDA
Topics
- Recalls and safety alertsMatched on
Safety Communication
- Drugs and medical devicesMatched on
MedWatch
Explore the named firms, organizations and MDL dockets above. Sources and method